{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:55:35Z","timestamp":1781175335686,"version":"3.54.1"},"reference-count":14,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,8,2]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>A 75-year-old man presented with shortness of breath and somnolence and was found to have urosepsis. Blood and urine cultures subsequently grew multidrug-resistant (MDR) <jats:italic>Klebsiella pneumoniae<\/jats:italic> (Kp) with the New Delhi metallo-\u03b2-lactamase gene. The patient was treated successfully with plazomicin and meropenem\/vaborbactam combination therapy. The course was complicated by acute kidney injury temporarily requiring haemodialysis, gastrointestinal bleed requiring multiple transfusions and hospital readmission with blood cultures again positive with MDR Kp. Plazomicin drug levels were persistently high during treatment, suggesting that therapeutic drug monitoring may be needed to safely use this drug in patients with severe renal dysfunction. This case marks the first use of plazomicin for bacteraemia in the literature outside of a clinical trial and demonstrates its safe and effective use in a patient with advanced renal disease, and provides important insights about dosing and therapeutic drug monitoring considerations in this patient population.<\/jats:p>","DOI":"10.1136\/bcr-2021-243609","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T17:47:02Z","timestamp":1650908822000},"page":"e243609","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Plazomicin for the treatment of multidrug-resistant <i>Klebsiella<\/i> bacteraemia in a patient with underlying chronic kidney disease and acute renal failure requiring renal replacement therapy"],"prefix":"10.1136","volume":"14","author":[{"given":"William","family":"Earle","sequence":"first","affiliation":[{"name":"Department of Medicine, VA Boston Healthcare System, West Roxbury, Massachusetts, USA"},{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n G B","family":"Bonegio","sequence":"additional","affiliation":[{"name":"Department of Medicine, VA Boston Healthcare System, West Roxbury, Massachusetts, USA"},{"name":"Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, VA Boston Healthcare System, West Roxbury, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Westyn","family":"Branch-Elliman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases, VA Boston Healthcare System, West Roxbury, Massachusetts, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"2025082711295483000_14.8.e243609.1","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"2025082711295483000_14.8.e243609.2","unstructured":"Cipla USA, Inc . ZEMDRI (Plazomicin) prescribing information. FDA. Available: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210303orig1s000lbl.pdf"},{"key":"2025082711295483000_14.8.e243609.3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.diagmicrobio.2018.07.006","article-title":"Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae","volume":"92","author":"Thwaites","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025082711295483000_14.8.e243609.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00873-15"},{"key":"2025082711295483000_14.8.e243609.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268819000256","article-title":"Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae","volume":"147","author":"Snyder","year":"2019","journal-title":"Epidemiol Infect"},{"key":"2025082711295483000_14.8.e243609.6","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S39186"},{"key":"2025082711295483000_14.8.e243609.7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz123"},{"key":"2025082711295483000_14.8.e243609.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807634"},{"key":"2025082711295483000_14.8.e243609.9","doi-asserted-by":"crossref","first-page":"e02040","DOI":"10.1128\/AAC.02040-18","article-title":"Diverse Vectors and Mechanisms Spread New Delhi Metallo-\u03b2-Lactamases among Carbapenem-Resistant Enterobacteriaceae in the Greater Boston Area","volume":"63","author":"Pecora","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082711295483000_14.8.e243609.10","unstructured":"Brown C . Carbapenemase-Producing organism (CPO) activity in Massachusetts. The Commonwealth of Massachusetts Department of Public Health Memo, 2019."},{"key":"2025082711295483000_14.8.e243609.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801467"},{"key":"2025082711295483000_14.8.e243609.12","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1095180"},{"key":"2025082711295483000_14.8.e243609.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz640"},{"key":"2025082711295483000_14.8.e243609.14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/ciz1064","article-title":"Plazomicin-associated nephrotoxicity","volume":"71","author":"Tang","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:30:04Z","timestamp":1756319404000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,19]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/bcr-2021-243609"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243609","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}